From B cells to lead molecules in
one week

Opto™ Plasma B Discovery using the Beacon® optofluidic system advances from B cells to lead molecules faster by putting function first.

In just one week, the workflow recovers 1000s of hits by screening up to 100,000 plasma B cells, down-selects lead molecules by profiling antibody function, and enables sequencing and re-expression of over 1000 functionally-characterized antibodies.

  • The ability to both multiplex and run sequential assays increases the screening resolution beyond what is possible in alternative single cell discovery platforms, making the Beacon in our opinion one of the most powerful high content screening tools in the industry.
    Tracey Mullen, MBA, CEO of Abveris
  • We've actually put this technology into practice in our antibody discovery work, and it takes about four months off the normal timeline. It's starting to feel like a pretty transformative tool
    Philip Tagari, Vice President of Therapeutic Discovery Amgen
  • One of the Beacon’s strongest advantages is finding the needle in the haystack. It has allowed us to overcome the limitations of hybridoma – we were able to increase yields by 10-fold.
    Iwona Budnicki, Genovac Antibody Discovery
Discover more hits against difficult multi-pass transmembrane targets like GPCRs

© Genovac Antibody Discovery LLC. All rights reserved.

 

Discover 10-fold more hits against difficult targets

The Opto™ Plasma B Discovery workflow increases the probability of success against difficult targets, or the “high-hanging fruit,” by directly screening B cells with assays to identify functional lead molecules.

Direct functional profiling of B cells can yield up to 10-fold more hits than hybridoma campaigns against difficult membrane targets like GPCRs.

Put function first

The Opto Plasma B Discovery workflow enables down-selection of lead candidates through multiple assays for antigen specificity, cross-reactivity, and function.

With a NanoPen™ chamber volume of only 250 picoliters, reactions are fast and precise. Complete assays in less than 1 hour, then reset your chips to enable the next assay to begin. This better characterization upfront reduces the expense of having to sequence or clone irrelevant non-functional hits.

ASSAYS THAT RUN IN OUR NANOPEN CHAMBERS

Antigen Specific Bead Assay

Ligand Blocking Assay

Cross-Species Assay

Reporter Cell Assay

Leave no hit behind

Beacon System’s OptoSelect™ Chip
Step 1: Cloning Into nanopen chambers
Step 2: Assay
Step 3: Barcoded CDNA Synthesis
Step 4: Bulk unload

The Opto Plasma B Discovery workflow enables automated recovery of thousands of hits by OptoSeq™ Barcoded BCR.

After functional profiling, mRNA is captured on barcoded beads for on-chip cDNA synthesis. Beads are recovered in bulk to enable accurate, high-throughput sequencing and re-expression of antibody paired heavy/light chain genes.

Sequence and re-express molecules with broad functional diversity

OptoSeq™ Barcoded BCR enables linkage of sequence to function by dual optical and genetic barcoding. The genetic barcodes read by NGS sequencing can be mapped to each bead, linking every antibody sequence to its corresponding function. Amplified cDNA is cloned into expression constructs in one step using Berkeley Lights’ Opto™ BCR Rapid Re-expression kit, which enables rapid re-expression of over 1000 functionally diverse antibodies for off-chip confirmation assays.

Advance lead molecules to the clinic faster

The Opto Plasma B Discovery workflow enables direct profiling of plasma B cells to find neutralizing antibodies using viral-specific blocking and binding assays.

This workflow has been used to deliver sequences of confirmed SARS-CoV-2 neutralizing antibodies to downstream manufacturing partners in just 18 days. Two of these antibodies form the basis of an AstraZeneca antibody cocktail for the treatment of COVID-19 currently in Phase III clinical trials.

Ready to discuss access options?

Ask us about purchase options including our new TechAccess Subscription.*

*Available in select regions